LLY

993.08

-0.02%↓

JNJ

204.51

+1.53%↑

ABBV

223.63

+0.22%↑

UNH

325.02

+0.62%↑

AZN

90.65

+0.6%↑

LLY

993.08

-0.02%↓

JNJ

204.51

+1.53%↑

ABBV

223.63

+0.22%↑

UNH

325.02

+0.62%↑

AZN

90.65

+0.6%↑

LLY

993.08

-0.02%↓

JNJ

204.51

+1.53%↑

ABBV

223.63

+0.22%↑

UNH

325.02

+0.62%↑

AZN

90.65

+0.6%↑

LLY

993.08

-0.02%↓

JNJ

204.51

+1.53%↑

ABBV

223.63

+0.22%↑

UNH

325.02

+0.62%↑

AZN

90.65

+0.6%↑

LLY

993.08

-0.02%↓

JNJ

204.51

+1.53%↑

ABBV

223.63

+0.22%↑

UNH

325.02

+0.62%↑

AZN

90.65

+0.6%↑

Home・Aandelen Lijst・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Open

SectorGezondheidszorg

84.01 0.85

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

82.53

Max

84.61

Belangrijke statistieken
By Trading Economics
Inkomsten	-16M 19M
Verkoop	13M 208M
K/W Sectorgemiddelde	95.379 77.671
Winstmarge	9.323
Werknemers	500
EBITDA	-11M 16M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+62.75% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	928M 8.7B
Vorige openingsprijs	83.16
Vorige sluitingsprijs	84.01

Nieuwssentiment

By Acuity

15%

85%

21 / 374 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 dec 2025, 22:13 UTC

Winsten

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec 2025, 21:40 UTC

Winsten

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec 2025, 16:57 UTC

Belangrijke Marktbewegers

Clear Secure Rises on Medicare Identity Verification Contract

9 dec 2025, 23:46 UTC

Marktinformatie

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec 2025, 23:46 UTC

Acquisities, Fusies, Overnames

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec 2025, 23:45 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec 2025, 23:44 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec 2025, 22:42 UTC

Winsten

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 21:48 UTC

Marktinformatie

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec 2025, 20:28 UTC

Marktinformatie

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec 2025, 20:26 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec 2025, 20:21 UTC

Marktinformatie

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec 2025, 19:52 UTC

Winsten

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec 2025, 19:17 UTC

Winsten

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 dec 2025, 17:11 UTC

Winsten

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

62.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 135.33 USD 62.75%

Hoogste 145 USD

Laagste 121 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corcept Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

21 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.